ZAK Inhibitor PLX4720 Promotes Extrusion of Transformed Cells via Cell Competition
Takeshi Maruyama,
Ayana Sasaki,
Sayuri Iijima,
Shiyu Ayukawa,
Nobuhito Goda,
Keisuke Tazuru,
Norikazu Hashimoto,
Takashi Hayashi,
Kei Kozawa,
Nanami Sato,
Susumu Ishikawa,
Tomoko Morita,
Yasuyuki Fujita
Affiliations
Takeshi Maruyama
Division of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University Graduate School of Chemical Sciences and Engineering, Sapporo 060-0815, Japan; Waseda Institute for Advanced Study, Waseda University, Tokyo 169-8050, Japan; Corresponding author
Ayana Sasaki
Division of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University Graduate School of Chemical Sciences and Engineering, Sapporo 060-0815, Japan
Sayuri Iijima
Division of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University Graduate School of Chemical Sciences and Engineering, Sapporo 060-0815, Japan
Shiyu Ayukawa
Department of Life Science and Medical Bioscience, School of Advanced Science and Engineering, Waseda University, Tokyo 162-8480, Japan
Nobuhito Goda
Department of Life Science and Medical Bioscience, School of Advanced Science and Engineering, Waseda University, Tokyo 162-8480, Japan
Keisuke Tazuru
Fujii Memorial Research Institute, Otsuka Pharmaceutical Co., Ltd., Shiga 520-0106, Japan
Norikazu Hashimoto
Fujii Memorial Research Institute, Otsuka Pharmaceutical Co., Ltd., Shiga 520-0106, Japan
Takashi Hayashi
Biomedical Technology Research Center, Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd., Tokushima 771-0192, Japan
Kei Kozawa
Division of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University Graduate School of Chemical Sciences and Engineering, Sapporo 060-0815, Japan
Nanami Sato
Division of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University Graduate School of Chemical Sciences and Engineering, Sapporo 060-0815, Japan
Susumu Ishikawa
Division of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University Graduate School of Chemical Sciences and Engineering, Sapporo 060-0815, Japan
Tomoko Morita
Division of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University Graduate School of Chemical Sciences and Engineering, Sapporo 060-0815, Japan
Yasuyuki Fujita
Division of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University Graduate School of Chemical Sciences and Engineering, Sapporo 060-0815, Japan; Department of Molecular Oncology, Graduate School of Medicine, Kyoto University, Kyoto, 606-8501, Japan; Corresponding author
Summary: Previous studies have revealed that, at the initial step of carcinogenesis, transformed cells are often eliminated from epithelia via cell competition with the surrounding normal cells. In this study, we performed cell competition-based high-throughput screening for chemical compounds using cultured epithelial cells and confocal microscopy. PLX4720 was identified as a hit compound that promoted apical extrusion of RasV12-transformed cells surrounded by normal epithelial cells. Knockdown/knockout of ZAK, a target of PLX4720, substantially enhanced the apical elimination of RasV12 cells in vitro and in vivo. ZAK negatively modulated the accumulation or activation of multiple cell competition regulators. Moreover, PLX4720 treatment promoted apical elimination of RasV12-transformed cells in vivo and suppressed the formation of potentially precancerous tumors. This is the first report demonstrating that a cell competition-promoting chemical drug facilitates apical elimination of transformed cells in vivo, providing a new dimension in cancer preventive medicine.